Recognition of early melanoma: a monocentric dermoscopy follow-up study comparing de novo
 melanoma with nevus-associated melanoma

AbstractNicolaides–Baraitser's syndrome is a rare, dominantly inherited well-delineated syndrome caused by mutations in the SMARCA2 gene which is located on the small arm of chromosome 9. In this study, a de novo missense variant, which was identified in a 3-year-old boy by whole exome sequencing is reported. The de novo heterozygous V1198M missense variant in SMARCA2 gene in exon 25 is novel. Identifying the condition is crucial for the long-term management and family counseling. Follow-up over 4 years revealed improvements in overall performance.

Download Full-text

A follow-up study of balloon angioplasty and de-novo stenting in Takayasu arteritis

International Journal of Cardiology ◽

10.1016/s0167-5273(00)00192-3 ◽

2000 ◽

Vol 75 ◽

pp. S147-S152 ◽

Cited By ~ 95

Author(s):

B.K Sharma ◽

S Jain ◽

H.K Bali ◽

A Jain ◽

S Kumari

Keyword(s):

Takayasu Arteritis ◽

Balloon Angioplasty ◽

De Novo ◽

Follow Up Study

Download Full-text

Cardiac sympathetic denervation and dementia in de novo Parkinson's disease: A 7-year follow-up study

Journal of the Neurological Sciences ◽

10.1016/j.jns.2017.09.010 ◽

2017 ◽

Vol 381 ◽

pp. 291-295 ◽

Cited By ~ 4

Author(s):

Mun Hee Choi ◽

Jung Han Yoon ◽

Suk Woo Yong

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

De Novo ◽

Sympathetic Denervation ◽

Follow Up Study ◽

Cardiac Sympathetic Denervation

Download Full-text

Early and late tamoxifen resistance in breast cancer

Archives of Biological Sciences ◽

10.2298/abs1002249a ◽

2010 ◽

Vol 62 (2) ◽

pp. 249-256

Author(s):

Rabi Abu ◽

M. Markicevic ◽

Tijana Vujasinovic ◽

Silvana Lukic ◽

Ljiljana Stamatovic ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

De Novo ◽

Clinical Course ◽

Tamoxifen Resistance ◽

Breast Cancer Patients ◽

Follow Up Study ◽

De Novo Resistance

In our study we investigated the role of the estrogen receptor (ER), progesterone receptor (PR) and clinicohistological parameters in breast cancer patients treated with tamoxifen during the early (2.5 years) vs. late (2.5-5 years) follow-up. The negative status of both ER and PR and tumors equal to or bigger than 2 cm defined the phenotypes and consequently the groups of patients with the worst clinical course of the disease: ER-negative PR-negative, ER-negative pT2 and PR-negative pT2. These high-risk subgroups were related to early follow-up indicating de novo resistance. It is relevant to point out that examined predictive indicators did not show significant importance in the late follow-up study.

Download Full-text

Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study

Journal of Transplantation ◽

10.1155/2014/171898 ◽

2014 ◽

Vol 2014 ◽

pp. 1-8 ◽

Cited By ~ 2

Author(s):

A. Thierry ◽

G. Mourad ◽

M. Büchler ◽

G. Choukroun ◽

O. Toupance ◽

...

Keyword(s):

Kidney Transplant ◽

De Novo ◽

Steroid Withdrawal ◽

Follow Up Study ◽

Transplant Patients ◽

Oral Steroids ◽

Kidney Transplant Patients ◽

Enteric Coated ◽

Steroid Avoidance

In a six-month, multicenter, open-label trial,de novokidney transplant recipients at low immunological risk were randomized to steroid avoidance or steroid withdrawal with IL-2 receptor antibody (IL-2RA) induction, enteric-coated mycophenolate sodium (EC-MPS: 2160 mg/day to week 6, 1440 mg/day thereafter), and cyclosporine. Results from a 30-month observational follow-up study are presented. Of 166 patients who completed the core study on treatment, 131 entered the follow-up study (70 steroid avoidance, 61 steroid withdrawal). The primary efficacy endpoint of treatment failure (clinical biopsy-proven acute rejection (BPAR) graft loss, death, or loss to follow-up) occurred in 21.4% (95% CI 11.8–31.0%) of steroid avoidance patients and 16.4% (95% CI 7.1–25.7%) of steroid withdrawal patients by month 36 (P=0.46). BPAR had occurred in 20.0% and 11.5%, respectively (P=0.19). The incidence of adverse events with a suspected relation to steroids during months 6–36 was 22.9% versus 37.1% (P=0.062). By month 36, 32.4% and 51.7% of patients in the steroid avoidance and steroid withdrawal groups, respectively, were receiving oral steroids. In conclusion, IL-2RA induction with early intensified EC-MPS dosing and CNI therapy inde novokidney transplant patients at low immunological risk may achieve similar three-year efficacy regardless of whether oral steroids are withheld for at least three months.

Download Full-text